Exclusion of other erosive-ulcerative oral disease and early recognition of HES in patients with oral ulcerations, and precise characterization of the lymphocytic or myeloproliferative form, are therefore important to rapidly initiate an effective therapy.
Introduction
Hypereosinophilic syndrome (HES) is a disorder characterized by persistent and marked eosinophilia complicated with end-organ damage (Hardy and Anderson, 1968) . Some HES forms have a poor prognosis, either because of an eosinophilic myocarditis followed by endomyocardial fibrosis, or because of an associated myeloid leukemia or malignant T cell lymphoma (Cogan et HAL author manuscript inserm-00151217, version 1 al., 1994; Roufosse et al., 2000; Simon et al., 1999) .
Oral mucosa ulcerations, when present, have been reported to be associated with severe forms of HES, and can be a presenting feature (Aractingi et al., 1996; Barouky et al., 2003; Billon et al., 1997; Leiferman et al., 1982) . Their precise characterization is important for early diagnosis and treatment, more especially as recent therapeutic advances have changed the prognosis of HES associated to myeloid proliferations.
Diagnostic criteria for Hypereosinophilic syndrome
Hardy and Anderson proposed for the first time in 1968 the concept of hypereosinophilic syndrome (HES). Diagnostic criteria of idiopathic HES were proposed in 1975 (Chusid et al., 1975 ):
a. blood eosinophilia (>1500 eosinophils /μL) for more than 6 months; b. exclusion of reactive eosinophilia caused by parasitic infections, allergies, eosinophilia associated with neoplasia; c. evidence of end-organ damage related to hypereosinophilia.
A National Institute of Health (NIH) conference in 1982 defined the clinical spectrum for idiopathic HES (Fauci et al., 1982) . It was not before 1994 that clonal proliferation of type 2 helper (Th2) T cells was reported in HES. The production of interleukine-5 (IL-5), a major mediator for eosinophil activation and survival, by the clonal T lymphocytes was further described, validating the concept of lymphocytic HES (L-HES) variant (Cogan et al., 1994; Roufosse et al., 2000; Simon et al., 1999) . In 2001, the dramatic response of certain forms of HES to a new drug, imatinib mesylate, a tyrosine kinase inhibitor efficient in chronic myeloid leukemia (CML) (Druker et al., 2001) led to a better characterization of a myeloid variant of HES (M-HES). A cytogenetic mutational deletion on HAL author manuscript inserm-00151217, version 1 chromosome 4 is constantly found in this M-HES variant, this deletion being specifically linked to tyrosine-kinase activity. Further cytogenetic studies led to the recognition of markers of response to imatinib (FIP1-like-1-platelet-derived growth factor receptor-α (FIP1L1-PDGFRA) fusion gene), and of resistance to this drug (Thr 674Ile mutation) (Cools et al., 2003; Gleich et al., 2002; Griffin et al., 2003; Pardanani et al., 2003; Wilkins et al., 2005) . As a result of the characterization of the lymphocytic (L-HES) and myeloproliferative (M-HES) variants of HES (summarized in Table I ), the field of "idiopathic "HES is now greatly reduced (Ballanger et al., 2006; Gleich and Leiferman, 2005) .
Clinical variants and outcome
A new clinical classification of hypereosinophilic syndromes has emerged from recent clinical and biological progresses (Gleich and Leiferman, 2005; Gotlib, 2005) .
The myeloproliferative HES variant (M-HES) is more often associated with mucosal ulcerations. It predominates in males and is characterized by hepatomegaly and splenomegaly. Blood tests show a persistent hypereosinophilia, an increased level of serum tryptase and vitamin B12, an altered leukocyte alkaline phosphatase score, chromosomal abnormalities, anemia and/or thrombocytopenia, and circulating leukocyte precursors (Klion et al., 2003) . The prognosis of the M-HES variant is poor, with severe cardiac complications, resistance to steroid therapy, and an increased risk of developing myeloid malignancies. Patients with M-HES can develop a blast crisis revealing an acute eosinophilic or myeloid leukemia. They can also develop a granulocytic sarcoma (Roufosse et al., 2003) . 
CD4
+ phenotype, express Th2 cytokines as IL-4, IL-5 and IL-13. These clonal T-cells are often detected in patients progressing to T cell lymphomas (Ravoet et al., 2005) .
Mucosal ulcerations are often associated with severe forms of HES with systemic involvement.
A major complication of severe HES, whatever the form, is endomyocardial fibrosis. It is the late stage of cardiac involvement, after early necrotic stage (rarely symptomatic), or thrombotic stage (intracavitary thrombi developing along the damaged endocardium) (Desreumaux et al., 1993) . In the late fibrotic stage with endomyocardial fibrosis, cardiac damage involves atrioventricular valves and induces congestive heart failure. Independently from endomyocardial lesions, peripheral thromboembolism related to an increased number of blood eosinophils may occur (Alter and Maisch, 2006; Mabilat-Pragnon et al., 1997) .
Clinical and pathological features of oral lesions in Hypereosinophilic syndrome
HES is a rare disorder with an estimated incidence rate of 0.5 to 1.0 cases per 100,000 per year.
In a recent study, emphasis was placed on mucosal ulcerations, considering this variant presentation of HES as commonly associated with the genetic change resulting in a gain-of-function gene (FIP1L1-PDGFRA), characteristic of patients with M-HES (Hofmann et al., 2006; Leiferman and Gleich, 2004) .
Cutaneous and mucosal signs occur in 27 to 64% of HES cases (Aractingi et al., 1996; Barouky et al., 2003; Kazmierowski et al., 1978; Leiferman et al., 1982) .
HES mucosal lesions can be ulcerations, erosions or aphthous lesions localized on the lips, gingival, tongue, palatine or jugal mucosa (Fig 1a) . They are characterized by discrete, round or oval ulcers, sometimes confluent, located on nonkeratinized, unattached mucosa such as buccal HAL author manuscript inserm-00151217, version 1 and labial mucosa, sulci, lateral and ventral tongue, soft palate, and oropharynx. Lesions are painful and may interfere with eating, speaking, or swallowing. These oral lesions may be associated with similar genital mucosa or conjunctival lesions.
Oral ulcerations from HES must be differentiated from ulcerations of other causes, mainly local traumas, malignant neoplasms, drug or irradiation-induced ulcerations. More numerous are the causes of oral ulcerations associated with systemic diseases: microbial diseases, bullous skin diseases, inflammatory bowel diseases and necrotic vasculitis (Scully, 1992a; Scully, 1992b) .
Ulcerated lesions from HES must also be differentiated from aphthae, either simple aphtosis, or recurrent aphthous stomatitis, recurrent oral and genital aphthae, and Behçet's disease. They are less difficult to differentiate from secondary complex aphtosis within HIV, Cyclic neutropenia, FAPA (fever, aphthous stomatitis, pharyngitis, adenitis), gluten sensitive enteropathy, hematinic deficiencies (iron, zinc, folate, vitamin B) (Letsinger et al., 2005) .
On hematoxylin-eosin stain, mucosal lesions contain, under an ulcerated epithelium, a polymorphous infiltrate composed of lymphocytes, plasma cells and macrophages, with some characteristic eosinophils, with bilobated nucleus and eosinophilic cytoplasm (Fig 1b) . A specific May-Grünwald-Giemsa stain is required to precisely assess the number of eosinophils and their distribution. Moreover, activated eosinophils often degranulate, with specific granules scattered in the intercellular space within inflammatory infiltrate. Antibodies directed against eosinophilic cationic proteins (eosinophil peroxidase -EPO, major basic protein -MBP, eosinophil cationic protein -ECP, eosinophil-derived neurotoxin -EDN) can be used on histological sections in order to identify eosinophils and the extracellular granules resulting from eosinophil degranulation (Fig   1c) .
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Electron microscopic examination (Fig 1 d) can be used to identify eosinophils, and their state of degranulation. When intact, they are characterized by cytoplasmic granules with a dense matrix and a crystallized central core. When observed at different stages of degranulation, they have an inverted density of the central cores of the cytoplasmic granules and a partially dissociated cytoplasm (Daneshpouy et al., 2002b; Janin et al., 1996) . Eosinophil activation can also lead to full cell lysis, with ultrastructural features associating with a necrotic nucleus, a disintegrated cytoplasm, and surrounding extracellular free granules (Colombel et al., 1990; Janin et al., 1994) .
The ultimate stage of eosinophil lysis results in the constitution of Charcot-Leyden crystals, with characteristic sharp and dense crystal shape . These Charcot-Leyden crystals are particularly resistant. They can be found in the tissue two to three weeks after the eosinophil lysis . They can also be detected in the blood and body fluids as broncho-alveolar lavage or urine (Dubucquoi et al., 1994) .
HES pathogenetic mechanisms
1 Eosinophil activation and induction of tissue damage
The release of cationic proteins through eosinophil degranulation and/or lysis can induce tissue damage, as demonstrated in vitro on helminthes and epithelial cells (Jong et al., 1981) . In human pathology, eosinophil infiltration predominates in mucosa, and eosinophil activation is observed in oral and bronchial mucosa of asthmatic patients (Gosset et al., 1995; Tsicopoulos et al., 2000) , in digestive tract of patients with eosinophilic gastroenteritis (Desreumaux et al., 1996) in both skin and duodenal mucosa of patients with dermatitis herpetiformis . The biological signs of eosinophilic activation in the blood are hypodense eosinophils. In the tissues, HAL author manuscript inserm-00151217, version 1 the pathological signs of eosinophil activation is characterized by the release of cationic proteins, the presence of hypodense granules on ultrastructural examination and the synthesis of IL-5.
Eosinophil activation is also associated with acute symptoms as flare-ups (Daneshpouy et al., 2002a; Tillie-Leblond et al., 1998; Vandezande et al., 1999) or early recurrences (Desreumaux et al., 1992; Dubucquoi et al., 1995) of inflammatory diseases, microvascular lesions and necrosis (Launay et al., 2000; Leiferman, 1991) . Release of cationic proteins (ECP and MBP) can also lead to lipid membrane disruption and target cell death (Weller, 1994) . In Hypereosinophilic syndromes, activated eosinophils are observed in early oral ulcerations (Aractingi et al., 1996; Leiferman et al., 1982) as in late endomyocardial fibrosis (Janin, 2005) .
Mechanisms of eosinophil chemotactism and activation
Eosinophils are derived from myeloid progenitors (granulocyte/erythrocyte/macrophage/ megakaryocyte-colony forming unit; GEMM-CFU) in bone marrow, through the action of three hematopoietic cytokines, granulocyte/macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5 (Sanderson, 1992) . Mature eosinophils are released into the blood stream and rapidly migrate towards their target tissues (Mishra et al., 1999; Rothenberg and Hogan, 2006; Wardlaw, 1999) . In physiological conditions, tissue eosinophils survival is short (24-48h) (Leiferman, 1991; Moqbel et al., 1994; Rothenberg, 1998) . In pathological conditions IL-5 prolongs tissue eosinophil survival (Collins et al., 1995; Matthews et al., 1998) . The main chemotactic mediators are eotaxin-1, eotaxin-2, eotaxin-3, and IL-5. IL-5 is also a major mediator for eosinophil activation and in situ survival (Clutterbuck and Sanderson, 1990; Rothenberg et al., 1997; Zimmermann et al., 2003) . IL-5 can be produced by different cells: lymphocytes, mastocytes, basophils and eosinophils themselves (Broide et al., 1992; Lorentz et al., 1999; Phillips et al., 2003; Till et al., 1997) . T-helper lymphocytes with a cytokine profile type Th2 In pathological conditions, eosinophilic recruitment, proliferation, and activation can be initially induced by an acquired abnormal genetic change of myeloid line (Gotlib et al., 2004; Keung et al., 2002) . This takes place in the context of an increased hematopoiesis, and is more frequently found in the M-HES variant, associated with myeloproliferative disorders.
Eosinophil recruitment and activation can also be induced by an overproduction of IL-5, IL-3 and GM-CSF (Desreumaux et al., 1998; Pazdrak et al., 1998) . This is observed mainly in the L-HES variant, as in hypereosinophilia associated with Hodgkin's disease, T-cell lymphomas or solid tumors (Bain, 2000; Ionescu et al., 2005) . Moreover, autocrine production of IL-5 by the eosinophil can contribute to chronic eosinophil infiltration (Desreumaux et al., 1996; Desreumaux et al., 1992; Desreumaux et al., 1993; Dubucquoi et al., 1994) .
Hypereosinophilic syndrome treatment
A new therapy is now proposed for different variants of HES, based on clinical and biological data.
Corticotherapy is a first line therapy. It is an efficient therapy, particularly for mucosal ulcerations, when HES has not yet been diagnosed. Topic or systemic steroids efficiently decrease eosinophilic activation and tissue recruitment by apoptosis induction (Gleich and Leiferman, 2005; Roufosse et al., 2003) .
M-HES targeted treatment
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Imatinib mesylate is a tyrosine kinase inhibitor (initially introduced for the treatment of CML), and it is the first choice treatment in M-HES, leading to a dramatic improvement (Gleich et al., 2002 ).
Imatinib's target is a novel kinase resulting from a 800 kb deletion on chromosome 4. cDNA derived from the fusion gene encoded a novel protein composed of the kinase domain of PDGFR-α linked to a previously uncharacterized gene resembling FIP1. This genetic rearrangement, initially found in the eosinophilic cell line EOL-1 (human acute myeloid (eosinophilic) leukemia, DSMZ ACC 386), was also detected in blood cells from patients with HES . A recent study of 16 HES patients showed that nine responded to imatinib, including all five with the FIP1L1-PDGFRA fusion gene. Furthermore, Ba/F3 (murine pro B cell, DSMZ ACC 300) cells expressing FIP1L1-PDGFRA were over 100-times more sensitive to imatinib than cells expressing breakpoint cluster region-Abelson (BCR-ABL) (Cools et al., 2003) .
The second generation of BCR-ABL tyrosine kinase inhibitors is used in imatinib-resistant HES (Tauchi and Ohyashiki, 2006) .
Other drugs used in M-HES treatment are hydroxyurea (Coutant et al., 1993; Varon et al., 1986; Weller and Bubley, 1994) , interferon alpha (Butterfield, 2005; Weller and Bubley, 1994) . If signs of malignant transformation are found, chemotherapy (Tanaka et al., 2006) or hematopoietic stem cell transplantation (HSCT) must be initiated (Fukushima et al., 1995) .
L-HES treatment
In the lymphocytic variant, steroids are very efficient and are the treatment of choice (Amano et al., 2005; Huntgeburth et al., 2005; Wallen et al., 1991; Weller and Bubley, 1994) . IFN-alpha can be associated to L-HES treatment (Schandene et al., 1996; Schandene et al., 2000; Yoon et al., 2000) . Other treatments are cyclosporin A (Nadarajah et al., 1997; Zabel and Schlaak, 1991) . If signs of malignant transformation are diagnosed, the treatment lines specific for T-cell lymphoma HAL author manuscript inserm-00151217, version 1 are proposed, with chemotherapy (Cyclophosphamide, Hydroxydoxorubicin, Oncovin, Prednisone; CHOP-like regimen) (Granel et al., 2000) , associated or not with monoclonal antibodies (Pitini et al., 2004; Sefcick et al., 2004) , fludarabine, 2-chlorodeoxyadenosine (2-CdA) (Jabbour et al., 2005; Ueno et al., 1997) . In resistant or recurrent cases, intensive high dose chemotherapy followed by HSCT can be used (Ueno et al., 2002) . Recently, a specific targeted therapy based on an anti-IL-5 monoclonal antibody mepolizumab (Garrett et al., 2004; Plotz et al., 2003; Simon et al., 2005; Sutton et al., 2005; Wilkins et al., 2005) has been proposed.
Conclusion
The field of "idiopathic hypereosinophilic syndromes" has been consistently reduced due to the better understanding of eosinophil biology. The therapeutic indications have also been completely changed by the efficiency of imatinib on the myeloproliferative forms of HES. The characterization of a fusion gene associated with the kinase target of imatinib offers to the physicians a biological marker to recognize patients who could benefit from this targeted therapy. Since oral mucosa ulcerations are more often associated to M-HES, and can be a presenting sign, oral physicians play a key role in the early recognition of M-HES, a necessary step for an efficient therapy.
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